Vision & Mission
Combining cancer vaccines
and T-cell therapies
ErVimmune develops breakthrough immunotherapies combining cancer vaccines and T-cell therapies based on the identification of new families of tumor antigens.
We are dedicated to discover more accurate tumor epitopes that are shared between patients. We focus on non-conventional epitopes derived from endogenous retroviruses (HERVs).
Our approach is based on new bioinformatics algorithms to identify potential epitopes that are validated by proteomics and immunology assays: from bioinformatics to proteomics.
ErVimmune is proud to be part of the new set of 47 companies selected to receive European Innovation Council (EIC) funding, combining grants and...
Here is the LinkedIn post from Paris Saclay Cancer Cluster: click here
ErVimmune Partners with Servier to Identify Regulatory Mechanisms of Endogenous Retroviruses in Tumors
Download the press release LYON, FRANCE October 11, 2023 – ErVaccine Technologies (now ErVimmune), a French biotechnology company developing...
Publications & abstracts
A new review article in Science Advances 2023 – TCR-engineered T cell therapy in solid tumors: State of the art and perspectives
Research article in American Journal of Hematology 2022 – HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy
Research Article in European Journal of Cancer journal 2022 – Tumor burden and antigen-specific T cell magnitude represent major parameters for clinical response to cancer vaccine and TCR-engineered T cell therapy
Medical research and development, in particular the development of new families of tumour antigens.
Research, development and production of monoclonal antibodies and derivatives targeting new membrane antigens and any other activity of any nature whatsoever related to the biotechnology and/or pharmaceutical industry.
> Publications & abstracts
> Recent news
> Legal notice
> About us
> Join us
28 RUE LAENNEC
69008 LYON FRANCE
+33 6 67 67 44 97